Acotiamide Oral Dosing for Dysuria Relief Without Cholinergic Crisis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cholinergic agents for treating urination disorders, such as underactive bladder, have insufficient voiding function improvement, reduce bladder compliance, worsen overactive bladder symptoms, and pose serious adverse effects like cholinergic crisis.
Innovation Solution
Acotiamide or its salt is administered orally in doses of 200 to 300 mg per administration, totaling 600 to 900 mg per day, for 2 to 3 times, to effectively alleviate urination disorders without causing serious adverse effects, suitable for long-term use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cholinergic agents are used to improve voiding function, then detrusor muscle contraction is enhanced, but bladder compliance decreases and overactive bladder symptoms worsen
Solution Approach 1:
The patent changes the chemical structure parameter of the agent by using acotiamide (a prokinetic agent with muscarinic receptor agonist activity) instead of conventional cholinergic agents. This structural change results in different pharmacological properties: acotiamide enhances detrusor contraction while preserving bladder compliance and not worsening overactive bladder symptoms, thus resolving the contradiction between improving voiding function and maintaining bladder compliance
2Productivity
If cholinergic agents are used to improve voiding function, then detrusor muscle contraction is enhanced, but cholinergic adverse effects occur
Solution Approach 1:
The patent changes the pharmacological parameter by selecting acotiamide, which has selective muscarinic M3 receptor agonist activity. This selectivity allows the drug to enhance detrusor contraction (improving voiding function) while minimizing stimulation of other muscarinic receptors in the gastrointestinal tract and other organs, thereby reducing cholinergic adverse effects such as diarrhea, abdominal pain, and sweating
3Productivity
If high-dose acotiamide is administered to achieve gastrointestinal motility improvement, then gastrointestinal motility is enhanced, but efficacy and tolerability at higher doses were not examined
Solution Approach 1:
The patent applies partial action by using a dose of acotiamide (100 mg three times daily) that is sufficient to achieve the desired therapeutic effect on voiding function without exceeding the dose range that has been shown to be safe and tolerable in gastrointestinal motility disorders. This approach ensures efficacy while maintaining tolerability
Solution Approach 2:
The patent leverages the known safety and tolerability profile of acotiamide from its extensive use in gastrointestinal motility disorders. The drug's established pharmacological properties and safety data from gastrointestinal applications serve as a foundation for its use in urinary disorders, allowing for safe dosing without requiring new safety studies at lower doses
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
An object of the present invention is to develop a urination disorder-alleviating agent which has a sufficient urination disorder improving effect and can be administered chronically. The present invention relates to a urination disorder-alleviating agent comprising acotiamide or a salt thereof as an active ingredient, wherein the acotiamide or a salt thereof is orally administered in an amount of 200 to 300 mg per administration for a total of 600 to 900 mg per day to an adult.